Chronic pain (CP) can profoundly strain family systems, yet few population studies have explored CP with high impact on families. We used 2023 National Health Interview Survey Data (n=29,522) to characterize CP with high impact on families of U.S. adults. Findings are: (1) the prevalence of CP with high impact on families (HICP-Family) is 4.4% in U.S. adults and 18.1% in U.S. adults with CP; (2) HICP-Family is almost exclusively reported by those who have high impact chronic pain (HICP) that limits their individual functioning in life and work; (3) yet, among those with HICP, not all (46.3%) report HICP-Family; (4) HICP-Family can feasibly be modeled as a latter transition stage in a tiered cascade of advancing CP-associated impacts; (5) there is a strong association between clinically significant mental health symptoms and HICP-Family; HICP-Family is six times more prevalent among those who screen positive for moderate-to-severe anxiety or depression symptoms. Families highly impacted by CP may not be adequately resourced for adaptive functional resilience. HICP-Family may form an underappreciated barrier to achieving optimal pain and mental health outcomes for people with HICP. Further, without intervention, members of families highly impacted by CP may face heightened susceptibility to onset of suboptimal pain and mental health trajectories of their own. The need to develop effective supports and promote adaptive resilience in families highly impacted by CP is clear. Clinical tools to support person-centered assessment of family and relational functioning, effective family-level interventions, and innovative models of care are needed.

IN BRIEF Establishes prevalence of chronic pain with high impact on families (HICP-Family); situates HICP-Family within emerging pain research frameworks.

The authors have declared no competing interest.

This study was funded by the Comprehensive Center for Pain & Addiction at the University of Arizona Health Sciences

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used ONLY openly available human data located at: https://www.cdc.gov/nchs/nhis/documentation/2023-nhis.html

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes